Aequus Pharmaceuticals (TSE:AQS) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Aequus Pharmaceuticals has secured an exclusive deal with Advanced Ophthalmic Innovations to distribute the PAUL® glaucoma drainage device in Canada, a product already approved in over 40 countries. The agreement enhances Aequus’s ophthalmology portfolio and leverages its existing sales infrastructure, aiming for a Canadian launch in Q4. The PAUL® device offers an innovative treatment option for patients with moderate to severe glaucoma, aligning with Aequus’s commitment to improving eyecare.
For further insights into TSE:AQS stock, check out TipRanks’ Stock Analysis page.